IP Library Granted Patent US 7,879,987
Granted Patent B2
US 7,879,987 · App. 11/840,854 · Granted Feb 1, 2011

Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,987
App. No.
11/840,854
Granted
Feb 1, 2011
Kind
B2
Abstract

The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.

Claims (11)

1. An isolated nucleic acid encoding a polypeptide comprising a heavy chain amino acid sequence selected from the group consisting of SEQ ID NOs: 2-6, 16, 20, 25, 28, and 31; and a light chain amino acid sequence selected from the group consisting of SEQ ID NOs: 8-12, 18, 22, 26, and 32.

2. The isolated nucleic acid of claim 1 , wherein the polypeptide comprises the amino acid sequences of SEQ ID NOs:2 and 8.

3. The isolated nucleic acid of claim 1 , wherein the polypeptide comprises the amino acid sequences of SEQ ID NOs:3 and 9.

4. The isolated nucleic acid of claim 1 , wherein the polypeptide comprises the amino acid sequences of SEQ ID NOs:4 and 10.

5. The isolated nucleic acid of claim 1 , wherein the polypeptide comprises the amino acid sequences of SEQ ID NOs:5 and 11.

6. The isolated nucleic acid of claim 1 , wherein the polypeptide comprises the amino acid sequences of SEQ ID NOs:6 and 12.

7. The isolated nucleic acid of claim 1 , wherein the polypeptide comprises the amino acid sequences of SEQ ID NOs:16 and 18.

8. The isolated nucleic acid of claim 1 , wherein the polypeptide comprises the amino acid sequences of SEQ ID NOs:20 and 22.

9. The isolated nucleic acid of claim 1 , wherein the polypeptide comprises the amino acid sequences of SEQ ID NOs:25 and 26.

10. The isolated nucleic acid of claim 1 , wherein the polypeptide comprises the amino acid sequences of SEQ ID NOs:28 and 26.

11. The isolated nucleic acid of claim 1 , wherein the polypeptide comprises the amino acid sequences of SEQ ID NOs:31 and 32.

Assignments (3)
CHANGE OF NAME Recorded Feb 18, 2013
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 029825/0070 →
CHANGE OF NAME Recorded Dec 7, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP.
Reel/Frame 025445/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022310/0517 →